AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

An international team of researchers led by Professor Morris Brown FRS at Queen Mary University of London found that ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...

Commonly used sulfonylureas were associated with an up to 13% increase in risk for major adverse CV events vs.

The initiative was launched by Parkway Shenton and Eu Yan San TCM Clinic. Parkway Shenton and Eu Yan Sang TCM Clinic have ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based on a ...

Struggling to control high BP? Learn about resistant hypertension, its causes, and expert-approved ways to manage it. Get insights to take charge of your blood pressure health.

Bedtime dosing with antihypertensive medication yields better nocturnal blood pressure control and improved circadian rhythm.

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

Recor Medical Supports Proposed CMS National Coverage Determination of Renal Denervation for the Treatment of Hypertension Provided by GlobeNewswire Jul 10, 2025, 10:47:42 PM ...

Know the hidden link between hypertension and fatty liver disease. Learn how high blood pressure can impact your liver health and what you can do to reduce your risk.